Exhibit 10.6
AN2 Therapeutics, Inc.
2022 Employee Stock Purchase Plan
Adopted by the Board of Directors: March 17, 2022
Approved by the Stockholders: March 18, 2022
IPO Date: March 25, 2022
2
.
3
.
4
.
5
.
6
.
The Company will seek to obtain from each U.S. and non-U.S. federal, state or other regulatory commission, agency or other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights.
7
.
8
.
The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board.
9
.
As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
10
.
11
.
12
.
13
.